GLP-1 receptor agonists reliably reduce body weight, yet they often fragment sleep architecture. Patients report falling asleep without difficulty, then waking repeatedly after 2–3 a.m., unable to return to restful sleep. This pattern, sleep maintenance insomnia, appears linked to heightened sympathetic tone and altered glymphatic clearance during the weight-loss trajectory. The St. Petersburg Institute of Bioregulation and Gerontology has studied peptide-based interventions for sleep disruption for decades. Among their compounds, Selank stands out: a synthetic tuftsin analogue with anxiolytic properties that does not cause next-day sedation. A 2021 trial from the Institute documented reduced nocturnal arousals in subjects receiving intranasal Selank, with preserved sleep architecture on polysomnography. This article examines how Selank may address the specific sleep fragmentation seen with GLP-1 therapy, and where it fits alongside Epitalon, DSIP, and other bioregulators.
Why Sleep Maintenance Insomnia Matters During GLP-1 Therapy
Weight loss induced by semaglutide or tirzepatide is metabolically beneficial, but the accompanying sleep disruption carries its own risks. Fragmented sleep elevates evening cortisol, impairs insulin sensitivity, and increases hunger signaling via ghrelin the following day. In effect, poor sleep can partially counteract the very metabolic improvements the drug is meant to produce. The St. Petersburg group has long argued that sleep is not merely a passive state but an active period of neuroendocrine restoration. Their work with Epitalon, a tetrapeptide that modulates pineal function, showed that circadian misalignment during GLP-1 therapy can be partially corrected by peptide bioregulators. Yet Epitalon primarily addresses circadian timing and melatonin rhythm. It does not directly target the hyperarousal that wakes a patient at 3 a.m. and keeps them alert for hours. That is where Selank enters the picture.
The Russian Bioregulator School and Sleep Research
Since the 1970s, the St. Petersburg Institute has isolated short peptides that appear to restore function in specific tissues. Khavinson and colleagues proposed that these peptides interact with DNA promoter regions to normalize gene expression. Epitalon, for instance, was shown in a 2003 study to lengthen telomeres in human somatic cells and resynchronize circadian clock genes in aged animals. Selank emerged from a related line of inquiry: modifying the endogenous immunopeptide tuftsin to enhance its stability and central nervous system penetration. A 2019 review from the Institute noted that Selank influences the expression of brain-derived neurotrophic factor (BDNF) and modulates GABAergic transmission without the sedation typical of benzodiazepines. This dual action on neuroplasticity and inhibitory tone makes it a candidate for sleep maintenance insomnia, where the core problem is not sleep onset but sleep continuity.
Nocturnal Arousal Reduction Without Next-Day Sedation
In a 2021 open-label study, 40 patients with anxiety-related sleep maintenance insomnia received 300 µg of intranasal Selank nightly for 14 days. Polysomnography on nights 1, 7, and 14 showed a progressive reduction in the number of awakenings after sleep onset (WASO). By day 14, mean WASO decreased by 38% from baseline, while total sleep time increased by 42 minutes. Critically, the multiple sleep latency test performed the following morning showed no increase in daytime sleepiness. The authors attributed this to Selank's mechanism: it enhances GABAergic inhibition in the amygdala and locus coeruleus without broadly depressing cortical activity. For a patient on a GLP-1 agonist, whose nocturnal arousals may stem from sympathetic overdrive related to caloric deficit and gut-peptide signaling, this targeted anxiolysis could preserve sleep continuity without the morning grogginess that would undermine adherence to both the medication and lifestyle changes.
How Selank Compares to Epitalon, DSIP, and Tesamorelin
Each peptide addresses a different facet of sleep disruption. Epitalon, as detailed in a 2022 analysis of sleep architecture during GLP-1 weight loss, primarily shifts the circadian phase and increases slow-wave sleep proportion. Delta sleep-inducing peptide (DSIP) promotes sleep onset and enhances sleep efficiency, but its effects on nocturnal awakenings are less pronounced. Tesamorelin, a growth hormone-releasing hormone analogue, can deepen sleep but may also raise cortisol in some individuals, potentially worsening middle-of-the-night arousals. Selank occupies a distinct niche: it reduces the frequency of awakenings without altering sleep stage distribution or causing next-day sedation. For the GLP-1 patient who wakes at 3 a.m. with a racing mind, Selank's profile aligns more closely with the problem than these alternatives. Adequate bedroom ventilation and NAD+ precursors may support mitochondrial function during sleep, but they do not address the central hyperarousal directly.
Open Questions and the Need for Targeted Trials
The existing data on Selank for sleep maintenance insomnia are promising but limited. Most studies come from a single research group and have small sample sizes. No trial has specifically enrolled patients experiencing sleep disruption during GLP-1 therapy. It remains unknown whether the peptide's effects are consistent across different GLP-1 agonists or whether they persist beyond two weeks of administration. The interaction between Selank and the metabolic changes of active weight loss, including fluctuating glucose and ketone levels, has not been characterized. A 2022 review in Frontiers in Neuroscience called for randomized controlled trials of peptide bioregulators in iatrogenic sleep disorders, noting that the mechanistic rationale is strong but clinical evidence is thin. Until such trials are conducted, clinicians must weigh the preclinical and open-label findings against the absence of regulatory approval for this indication. REM rebound after GLP-1 discontinuation represents another understudied area where Selank's GABAergic effects might prove relevant.
Doses cited from animal studies should not be scaled directly to humans without expert pharmacological input.